Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Litfulo and Brepocitinib in Alopecia Areata
NCT02974868Phase 2Completed
- Sponsor
- Pfizer
- Start
- Dec 2016
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial in alopecia areata comparing Litfulo, Brepocitinib and Placebo (3 arms). Primary endpoints: Change From Baseline in Severity of Alopecia Tool (SALT) Score at 24 weeks, Number of Participants With Treatment-emergent Adverse Events - Single-Blind Extension and 3 more. Started Dec 2016; status: completed.
02
Drugs
ritlecitinib tosilatebrepocitinib
03
Conditions
alopecia areata
Beyond the preview
Go deeper on NCT02974868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02974868.